02292nas a2200229 4500008004100000245010100041210007100142260001300213300001200226490000700238520158600245653001601831653001601847653001201863653001301875653001901888100003101907700001801938700002201956700002201978856006202000 2020 eng d00aBanisterine Alleviates Morphine‑based Nephrotoxicity by Antioxidant Property: An In vivo Study0 aBanisterine Alleviates Morphine‑based Nephrotoxicity by Antioxid cMay 2021 a137-1420 v123 a

Background: Banisterine (BAN) as an alkaloid agent has antioxidant properties. The morphine (MOR) with the character of free radical generation has an effective role on renal pathogenesis. Objectives: This investigation critically examines the effects of the BAN against MOR‑induced damage to the kidneys of rats. Materials and Methods: Sixty‑four male Wistar rats were randomly assorted into 8 groups (8 rats in each), including the saline (Sal), MOR, BAN (5, 10, 15 mg/kg) and MOR + BAN treatment groups. All experimental procedures were applied by intraperitoneal injection daily for 20 days. Whole investigated values consist of total animal weight, weight of kidney, morphological criteria of kidney, antioxidant capacity and serum nitrite oxide levels. Results: Intraperitoneally MOR application significantly increased the levels of renal Malondialdehyde (MDA), blood urea nitrogen (BUN), blood creatinine, and blood nitrite oxide and also reduced the glomerular number and tissue ferric reducing/antioxidant power (FRAP) level compared to the Sal control group (P < 0.05). Treatment of BAN and BAN + MOR in all doses significantly reduced the levels of BUN, MDA, creatinine, glomerular diameter, and nitrite oxide and also increased the glomerular number and tissue FRAP levels compared to the MOR group (P < 0.05). Conclusion: The findings support the idea that the BAN with its antioxidant nature can eliminate MOR renal toxicity.

10aAntioxidant10aBanisterine10ain vivo10aMorphine10aNephrotoxicity1 aSalahshoor, Mohammad, Reza1 aJalili, Cyrus1 aAbdolmaleki, Amir1 aRoshankhah, Shiva uhttps://www.phcogres.com/article/2020/12/2/104103prpr9719